Trodelvy — Total revenues
Gilead Sciences Trodelvy — Total revenues increased by 5.0% to $402.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 37.2%, from $293.00M to $402.00M. Over 3 years (FY 2022 to FY 2025), Trodelvy — Total revenues shows an upward trend with a 27.1% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase indicates growing market penetration, successful expansion into new patient populations, or effective commercial execution for this specific therapy. A decrease may signal increased competition, loss of market share, or challenges in clinical adoption.
Detailed definition
This metric represents the total gross sales generated from the Trodelvy product line, a key therapeutic asset in the co...
Peer comparison
Comparable to oncology product revenue lines at other biopharmaceutical companies, often benchmarked against the growth rates of competing targeted therapies in the breast cancer or solid tumor markets.
gild_segment_trodelvy_total_revenuesHistorical Data
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $170.00M | $170.00M | $170.00M | $170.00M | $265.75M | $265.75M | $265.75M | $265.75M | $309.00M | $320.00M | $332.00M | $354.00M | $293.00M | $364.00M | $357.00M | $383.00M | $402.00M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +56.3% | +0.0% | +0.0% | +0.0% | +16.3% | +3.6% | +3.8% | +6.6% | -17.2% | +24.2% | -1.9% | +7.3% | +5.0% |
| YoY Change | — | — | — | — | +56.3% | +56.3% | +56.3% | +56.3% | +16.3% | +20.4% | +24.9% | +33.2% | -5.2% | +13.8% | +7.5% | +8.2% | +37.2% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Gilead Sciences's trodelvy — total revenues?
- Gilead Sciences (GILD) reported trodelvy — total revenues of $402.00M in Q1 2026.
- How has Gilead Sciences's trodelvy — total revenues changed year-over-year?
- Gilead Sciences's trodelvy — total revenues increased by 37.2% year-over-year, from $293.00M to $402.00M.
- What is the long-term trend for Gilead Sciences's trodelvy — total revenues?
- Over 3 years (2022 to 2025), Gilead Sciences's trodelvy — total revenues has grown at a 27.1% compound annual growth rate (CAGR), from $680.00M to $1.40B.
- What does trodelvy — total revenues mean?
- The total amount of money earned from sales of the Trodelvy drug product line.